SAP-001 is a novel, clinical stage (IIb) small molecule designed to address the large and growing unmet medical needs associated with refractory and tophaceous gout. We believe that SAP-001 is the First-in-Class to offer a complete solution for gout and hyperuricemia, and has the potential to become the Best-in-Class treatment for refractory and/or tophaceous gout patients and for patients that are not well controlled on allopurinol and/or febuxostat, a sizable market with a revenue potential of over $1 billion in the US alone.

Over time, We believe that SAP-001 has the potential to become the treatment of choice for gout and hyperuricemia.